How to manufacture the stable amorphous hybrid nanoparticle containing at least one sort of protein-kinases inhibitor, and at least one sort of polymer stabilization matrix formation ingredients

Title:

How to manufacture the stable amorphous hybrid nanoparticle containing at least one sort of protein-kinases inhibitor, and at least one sort of polymer stabilization matrix formation ingredients

Document Type and Number:

Japanese Patent JP6238310

Kind Code:

B2

Abstract:

The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

More Like This:

JP2023542042	Indoline compounds and derivatives as EGFR inhibitors
JP2013542215	N-hetalyl methylpyrazolylcarboxamides
WO/2009/092442	TREATMENT OF PORTAL HYPERTENSION AND RELATED CONDITIONS BY COMBINED INHIBITION OF THE VEGF AND PDGF SIGNALLING PATHWAYS

Inventors:

Brisander, Magnus
Demilbuquel, Mustafa
Yeson, Gerald
Malmsten, Martin
Deland, Helene

Application Number:

JP2014552153A

Publication Date:

November 29, 2017

Filing Date:

January 11, 2013

Export Citation:

Click for automatic bibliography generation Help

Assignee:

XSpray Pharma AB(publ)

International Classes:

A61K31/506; A61K9/14; A61K47/32; A61K47/34; A61K47/38; A61P35/00; A61P43/00; B01F23/00

Domestic Patent References:

JP2009540010A
JP2009543797A
JP2003508419A
JP2011526836A
JP2010509289A

Attorney, Agent or Firm:

Patent business corporation Kita Aoyama International

Previous Patent: A method for generating the snapshot of the volume which has the unity between applications and whic...

Next Patent: DISTANCE MEASURING INSTRUMENT